Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer
19. November 2024 09:15 ET
|
Kaida Biopharma
Company appoints Anil K. Sood, MD, as inaugural member Company continues to advance lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1 study, targeted for 2025...